Patents by Inventor Philippe Barthelemy

Philippe Barthelemy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240052351
    Abstract: The invention relates to an inhibitor of FXYD2 wherein said inhibitor reduces the expression and/or activity of FXYD2 in a subject in need thereof and targets at least the region comprising or consisting of the nucleotides 219-229 of SEQ ID NO: 3. Inventors have shown that targeting a region of FXYD2 can be used to inhibit and/or reduce the expression and/or activity of FXYD2. They have designed and synthesized an antisense oligonucleotide (SEQ ID NO: 4) targeting the rat and human FXYD2 gene. The have performed intrathecal injection of FXYD2 optimized ASO in two rat models of pain (neuropathic and inflammatory pain). They have shown that FXYD2 ASO efficiently reduces its expression in rat Dorsal root ganglion (DRG). The have demonstrated that FXYD2 ASO dramatically reduces neuropathic pain in the Spinal Nerve Ligation (SNL) rat model and analgesic effect of FXYD2 ASO on neuropathic pain is greater than that of Ziconotide, the current market leader.
    Type: Application
    Filed: October 9, 2020
    Publication date: February 15, 2024
    Inventors: Stéphanie Venteo, Patrick Carroll, Philippe BARTHELEMY, Sébastien BENIZRI, Alexandre Pattyn
  • Publication number: 20220220481
    Abstract: The present invention relates to the treatment of infections due to antibiotic-resistant bacteria. Antimicrobial resistance (AMR) has been observed at dangerously high levels worldwide and alternative strategies are urgently needed. Antisense therapy has been identified as potential therapeutic tool for tackling AMR. However, in the context of AMR, since the antisense oligonucleotides have to reach the target mRNA to be efficient, the cellular uptake inside prokaryotic cells is a critical issue. The inventors demonstrated that antisense oligonucleotide sequences, in particular targeting the blaCTX/M15 gene, featuring a lipid moiety conjugated to the ASO extremity show a particularly efficient intracellular penetration in prokaryotic cells and that these lipid-modified antisense oligonucleotides can show a further improved enzymatic stability with phosphorothioate chemistry (PTO).
    Type: Application
    Filed: May 7, 2020
    Publication date: July 14, 2022
    Inventors: Tina KAUSS, Corinne ARPIN, Philippe BARTHELEMY, Phuoc Vinh NGUYEN
  • Publication number: 20210363036
    Abstract: The invention relates to a method for decontaminating an aqueous liquid medium containing molecular micropollutants or a surface contaminated with micropollutants using nucleolipid compounds.
    Type: Application
    Filed: February 22, 2019
    Publication date: November 25, 2021
    Inventors: Philippe BARTHELEMY, Sylvie CRAUSTE-MANCIET, Marc SICARD
  • Publication number: 20200181607
    Abstract: The present invention relates to tetramolecular parallel G-quadruplex-forming oligonucleotides. If G-quadruplexes are of prime importance in biology, their use is hampered by the propensity of G4-prone DNA molecules, in particular G4-prone DNA molecules of long size, to adopt many different G4 topological conformations or other alternative foldings. By introducing a lipid modification at the end of the oligonucleotide, the inventors succeeded in obtaining long tetramolecular parallel G-quadruplexes (tpG4). The present invention thus concerns an oligonucleotide modified by substitution at the 5? or the 3? end by a lipid moiety, wherein said oligonucleotide comprises a nucleic acid sequence of at least 10 nucleotides, said nucleic acid sequence including a series of at least 4 consecutive guanine residues located in the middle of said sequence.
    Type: Application
    Filed: June 1, 2018
    Publication date: June 11, 2020
    Inventors: Philippe BARTHELEMY, Arnaud GISSOT, Brune VIALET
  • Patent number: 10633408
    Abstract: The invention relates to new nucleoside-lipid compounds with pH-sensitive dialkylorthoester chains, to the process for their preparation and to their uses, in particular their use for transportation or vectorization of at least one therapeutic agent.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: April 28, 2020
    Assignees: UNIVERSITE DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Philippe Barthelemy, Khalid Oumzil
  • Patent number: 10633409
    Abstract: The invention relates to bola-amphiphilic compounds and their uses for biomedical application. The invention particularly relates to the use of bola-amphiphilic compounds for providing low molecular weight gels (LMWG), useful, in particular, as culture media for animal or human cells, or as biocompatible material for biomedical applications.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: April 28, 2020
    Assignees: UNIVERSITE DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Philippe Barthelemy, Michael Ramin, Laurent Latxague, Ananda Appavoo, Olivier Chassande, Camille Ehret
  • Publication number: 20190233460
    Abstract: The invention relates to bola-amphiphilic compounds and their uses for biomedical application. The invention particularly relates to the use of bola-amphiphilic compounds for providing low molecular weight gels (LMWG), useful, in particular, as culture media for animal or human cells, or as biocompatible material for biomedical applications.
    Type: Application
    Filed: January 18, 2019
    Publication date: August 1, 2019
    Inventors: Philippe BARTHELEMY, Michael RAMIN, Laurent LATXAGUE, Ananda APPAVOO, Olivier CHASSANDE, Camille EHRET
  • Patent number: 10343934
    Abstract: The present invention relates to the use of a supramolecular system in order to remove particles from a liquid medium containing same. According to the invention, the supramolecular system includes at least one molecule having a low molecular weight and/or an organic compound from living organisms, preferably from jellyfish, said compound being selected from among collagen, a polysaccharide, a proteoglycan or a mixture of two of said organic compounds, and said molecule having a low molecular weight and formula (I) as defined herein. The invention also relates to a method for removing particles from a liquid medium containing same. The invention is particularly suitable for use in water decontamination and biotechnology.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: July 9, 2019
    Assignee: UNIVERSITE DE BORDEAUX
    Inventors: Philippe Barthelemy, Alain Thiery, Amit Patwa
  • Patent number: 10227372
    Abstract: The invention relates to bola-amphiphilic compounds and their uses for biomedical application. The invention particularly relates to the use of bola-amphiphilic compounds for providing low molecular weight gels (LMWG), useful, in particular, as culture media for animal or human cells, or as biocompatible material for biomedical applications.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: March 12, 2019
    Assignees: UNIVERSITE DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Philippe Barthelemy, Michael Ramin, Laurent Latxague, Ananda Appavoo, Olivier Chassande, Camille Ehret
  • Publication number: 20180118775
    Abstract: The invention relates to new nucleoside-lipid compounds with pH-sensitive dialkylorthoester chains, to the process for their preparation and to their uses, in particular their use for transportation or vectorization of at least one therapeutic agent.
    Type: Application
    Filed: May 19, 2016
    Publication date: May 3, 2018
    Inventors: Philippe BARTHELEMY, Khalid OUMZIL
  • Publication number: 20180116972
    Abstract: The invention relates to non-polymeric lipid-based nanocarrier compositions loaded with metal nanoparticles and at least one therapeutic agent, useful agents for transportation, vectorization, cellular delivery cellular targeting or cellular localization of at least one therapeutic agent.
    Type: Application
    Filed: April 20, 2016
    Publication date: May 3, 2018
    Inventors: Philippe BARTHELEMY, Khalid OUMZIL, Gisèle CLOFENT-SANCHE, Marie-Josée JACOBIN-VALAT, Jeanny LAROCHE-TRAINEAU, Stéphane MORNET, Karen GAUDIN, Abdelmajid NOUBHANI, Xavier-Fran?ois SANTARELLI
  • Publication number: 20170240583
    Abstract: The invention relates to bola-amphiphilic compounds and their uses for biomedical application. The invention particularly relates to the use of bola-amphiphilic compounds for providing low molecular weight gels (LMWG), useful, in particular, as culture media for animal or human cells, or as biocompatible material for biomedical applications.
    Type: Application
    Filed: October 6, 2015
    Publication date: August 24, 2017
    Inventors: Philippe BARTHELEMY, Michael RAMIN, Laurent LATXAGUE, Ananda APPAVOO, Olivier CHASSANDE, Camille EHRET
  • Patent number: 9707250
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least three saturated or unsaturated, linear or branched hydrocarbon chains comprising from 2 to 30 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 18, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE BORDEAUX, Université d' Aix-Marseille, Institut Jean Paoli & Irene Calmettes, Centre Régional de Lutte Contre le Cancer, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
    Inventors: Philippe Barthelemy, Khalid Oumzil, Arnaud Gissot, Palma Rocchi, Julie Acunzo
  • Patent number: 9701962
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least one ketal functional group, wherein the ketal carbon of said ketal functional group bears two saturated or unsaturated, linear or branched, hydrocarbon chains comprising from 1 to 22 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 11, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE BORDEAUX, UNIVERSITE D 'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Philippe Barthelemy, Khalid Oumzil, Palma Rocchi, Julie Acunzo
  • Patent number: 9533049
    Abstract: The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorization of therapeutic agents, especially anti-tumoral agents.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 3, 2017
    Assignees: UNIVERSITE D'AIX-MARSEILLE, UNIVERSITE DE BORDEAUX, UNIVERSITÉ DE BOURGOGNE
    Inventors: Philippe Barthelemy, Michel Camplo, Nathalie Campins, Bruno Chauffert, Florence Bouyer
  • Publication number: 20160113957
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least three saturated or unsaturated, linear or branched hydrocarbon chains comprising from 2 to 30 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Application
    Filed: June 5, 2014
    Publication date: April 28, 2016
    Inventors: Philippe BARTHELEMY, Khalid OUMZIL, Arnaud GISSOT, Palma ROCCHI, Julie ACUNZO
  • Publication number: 20160108398
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least one ketal functional group, wherein the ketal carbon of said ketal functional group bears two saturated or unsaturated, linear or branched, hydrocarbon chains comprising from 1 to 22 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Application
    Filed: June 5, 2014
    Publication date: April 21, 2016
    Inventors: Philippe Barthelemy, Khalid Oumzil, Palma Rocchi, Julie Acunzo
  • Patent number: 9050268
    Abstract: The invention relates to novel functional amphiphilic molecule or macromolecule formulations with multiple compartments for transporting or targeting at least one therapeutic agent, in particular an antitumor agent, as well as to a method for preparing such formulations and to the use thereof.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: June 9, 2015
    Assignees: UNIVERSITE d'AIX-MARSEILLE, UNIVERSITE DE BORDEAUX
    Inventors: Philippe Barthelemy, Salim Khiati, Michel Camplo
  • Publication number: 20150076062
    Abstract: The present invention relates to the use of a supramolecular system in order to remove particles from a liquid medium containing same. According to the invention, the supramolecular system includes at least one molecule having a low molecular weight and/or an organic compound from living organisms, preferably from jellyfish, said compound being selected from among collagen, a polysaccharide, a proteoglycan or a mixture of two of said organic compounds, and said molecule having a low molecular weight and formula (I) as defined herein. The invention also relates to a method for removing particles from a liquid medium containing same. The invention is particularly suitable for use in water decontamination and biotechnology.
    Type: Application
    Filed: January 25, 2013
    Publication date: March 19, 2015
    Inventors: Philippe Barthelemy, Alain Thiery, Amit Patwa
  • Publication number: 20140308343
    Abstract: The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorization of therapeutic agents, especially anti-tumoral agents.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 16, 2014
    Applicants: UNIVERSITE VICTOR SEGALEN BORDEAUX 2, UNIVERSITE DE LA MEDITERRANEE, UNIVERSITE DE BOURGOGNE
    Inventors: Philippe BARTHELEMY, Michel CAMPLO, Nathalie CAMPINS, Bruno CHAUFFERT, Florence BOUYER